Kisspeptin-10
low riskAlso: KP-10 · Metastin 45-54
Kisspeptin-10 is the biologically active C-terminal decapeptide of kisspeptin, retaining full GPR54 receptor activity. It is extensively used in human pharmacology research for HPG axis studies and has potential therapeutic applications in male hypogonadism and fertility.
Reported Benefits
Testosterone Stimulation
Subcutaneous kisspeptin-10 reliably stimulates LH and testosterone in hypogonadal men.
Male Fertility
Stimulates testicular function in men with certain forms of hypogonadotropic hypogonadism.
Ovulation Induction
Small trials suggest potential as ovulation trigger alternative to hCG.
Mechanism of Action
Kisspeptin-10 (the C-terminal decapeptide) activates GPR54 (KISS1R) on hypothalamic GnRH neurons, triggering GnRH pulse release and subsequent LH/FSH-driven gonadal steroidogenesis. The minimal active fragment retains full agonist activity at GPR54.
Key Clinical Studies
Jayasena CN et al. (2011)
crossover · 12 men with T2DM
KP-10 restored LH pulsatility and testosterone in hypogonadal men
Overview
Kisspeptin-10 is the minimal active fragment of kisspeptin, representing the C-terminal 10 amino acids (positions 45-54 of full-length kisspeptin-54). It retains full biological activity at GPR54 receptors while being significantly more synthetically accessible than the full 54-amino acid parent peptide.
Male Hypogonadism Application
The most clinically relevant application of KP-10 research is in male hypogonadism — specifically forms where the HPG axis is intact but not adequately stimulated. In these patients, KP-10 can reliably stimulate LH secretion and testosterone production, raising the prospect of fertility-preserving hypogonadism treatment.
IVF Protocol Alternative
The use of kisspeptin as an ovulation trigger in IVF — as an alternative to hCG — has been studied at Hammersmith Hospital in London. The rationale is that kisspeptin triggers a more physiological LH surge through hypothalamic-pituitary activation rather than direct LH receptor stimulation, potentially reducing ovarian hyperstimulation syndrome risk.
Development Status
Kisspeptin receptor agonists are under active pharmaceutical development by several companies, particularly for infertility indications. KP-10 is the primary research tool compound driving this development pipeline.
Regulatory Status
Research OnlyNot FDA-approved; human pharmacology data available
Safety Profile
Side Effects
- •Nausea (injection)
- •Transient flushing
Contraindications
- •Hormone-sensitive cancers
Drug Interactions
- •GnRH analogs
- •Testosterone therapy (monitoring required)
Primary Uses
Related Peptides
Weekly Briefing
Regulatory updates + new study breakdowns.
For Practitioners
Do you prescribe Kisspeptin-10?
Get in front of patients who've already researched this protocol and are ready to consult. Featured listings from $199/mo.
Get Listed →